Nasdaq · CIK 0001661053
NVNO enVVeno Medical Corp
Insider trading from SEC Form 4. Last filing 29 d ago. Close $8.75 on Oct 9, 2026, +12% from the 52-week low and -73% from the high.
enVVeno Medical Corp (NVNO) has 25 SEC Form 4 filings on file from 8 insiders, the latest filed on Sep 14, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $123, net -$123.
10 open-market trades have been scored at NVNO. The newest: Francis Duhay (director) sold $123 of stock on Sep 11, 2026, filed Sep 14, 2026, scored 0 (weak), under a 10b5-1 plan. The largest of the 10 shown: Francis Duhay (director) bought $250k on Dec 31, 2024, scored 53 (moderate). 5 insiders bought within 14 days of each other around Dec 31, 2024.
NVNO closed at $8.75 on Oct 9, 2026, 12% above its 52-week low and 73% below its 52-week high.
1 Form 144 notice of planned sales is on file, the latest filed Sep 15, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at enVVeno Medical Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Francis Duhay director sell | $123 11 shares | -0% | - | |
| 0Weak | Francis Duhay director sell | $1,443 140 shares | -6% | +18% from low-94% from high | |
| 0Weak | Francis Duhay director sell | $1,613 140 shares | -5% | +27% from low-94% from high | |
| 0Weak | Francis Duhay director sell | $1,742 4,900 shares | -5% | +11% from low-93% from high | |
| 0Weak | Francis Duhay director sell | $4,067 4,900 shares | -5% | +27% from low-83% from high | |
| 53Moderate | Francis Duhay director buy | $250k 81,433 shares | +389% | - | |
| 36Weak | Robert Gray director buy | $10k 3,500 shares | +46% | - | |
| 40Moderate | Sanjay Shrivastava director buy | $16k 5,400 shares | +139% | - | |
| 40Moderate | Matthew Jenusaitis director buy | $24k 9,620 shares | +139% | - | |
| 48Moderate | Robert Andrew Berman Chief Executive Officer buy | $31k 12,000 shares | +6% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 15, 2025 | Duhay Francis Director | 9,800 0.05% of outstanding | $8,143 | Sep 15, 2025 | none |
Transactions
Every row filed, 25 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Francis Duhay director | SOpen-market sale Common Stock10b5-1 | -11 | $11.21 | $123 | 2,351 | 29 d ago |
| Jun 11, 2026 | Francis Duhay director | SOpen-market sale Common Stock10b5-1 | -140 | $10.31 | $1,443 | 2,362 | Jun 12, 2026 |
| Mar 12, 2026 | Francis Duhay director | SOpen-market sale Common Stock10b5-1 | -140 | $11.52 | $1,613 | 2,502 | Mar 13, 2026 |
| Dec 16, 2025 | Hamed Alavi Chief Technology Officer | JOther Restricted Stock Unitsderivative | -50,000 | $0.00 | $0 | 0 | Dec 18, 2025 |
| Dec 16, 2025 | Robert Andrew Berman Chief Executive Officer | JOther Restricted Stock Unitsderivative | -200,000 | $0.00 | $0 | 0 | Dec 18, 2025 |
| Dec 16, 2025 | Marc H. Glickman SVP & Chief Medical Officer | JOther Restricted Stock Unitsderivative | -100,000 | $0.00 | $0 | 0 | Dec 18, 2025 |
| Dec 11, 2025 | Francis Duhay director | AGrant or award Stock Optionsderivative | +135,883 | $0.00 | $0 | 135,883 | Dec 15, 2025 |
| Dec 11, 2025 | Robert Gray director | AGrant or award Stock Optionsderivative | +135,883 | $0.00 | $0 | 135,883 | Dec 15, 2025 |
| Dec 11, 2025 | Matthew Jenusaitis director | AGrant or award Stock Optionsderivative | +135,883 | $0.00 | $0 | 135,883 | Dec 15, 2025 |
| Dec 11, 2025 | Sanjay Shrivastava director | AGrant or award Stock Optionsderivative | +135,883 | $0.00 | $0 | 135,883 | Dec 15, 2025 |
| Dec 11, 2025 | Francis Duhay director | SOpen-market sale Common Stock10b5-1 | -4,900 | $0.36 | $1,742 | 92,544 | Dec 12, 2025 |
| Sep 15, 2025 | Francis Duhay director | SOpen-market sale Common Stock10b5-1 | -4,900 | $0.83 | $4,067 | 97,444 | Sep 17, 2025 |
| May 19, 2025 | Jennifer Bright Chief Financial Officer | AGrant or award Stock Optionsderivative | +350,000 | $0.00 | $0 | 350,000 | May 20, 2025 |
| Dec 31, 2024 | Francis Duhay director | POpen-market purchase Common Stock | +81,433 | $3.07 | $250k | 102,344 | Jan 3, 2025 |
| Dec 31, 2024 | Robert Gray director | POpen-market purchase Common Stock | +3,500 | $2.94 | $10k | 11,155 | Jan 2, 2025 |
| Dec 24, 2024 | Sanjay Shrivastava director | POpen-market purchase Common Stock | +5,400 | $2.90 | $16k | 9,288 | Dec 26, 2024 |
| Dec 19, 2024 | Matthew Jenusaitis director | POpen-market purchase Common Stock | +9,620 | $2.53 | $24k | 16,545 | Dec 23, 2024 |
| Dec 18, 2024 | Hamed Alavi Chief Technology Officer | AGrant or award Stock Optionsderivative | +75,000 | $0.00 | $0 | 75,000 | Dec 20, 2024 |
| Dec 18, 2024 | Robert Andrew Berman Chief Executive Officer | AGrant or award Stock Optionsderivative | +200,000 | $0.00 | $0 | 200,000 | Dec 20, 2024 |
| Dec 18, 2024 | Francis Duhay director | AGrant or award Stock Optionsderivative | +19,752 | $0.00 | $0 | 19,752 | Dec 20, 2024 |
| Dec 18, 2024 | Marc H. Glickman SVP & Chief Medical Officer | AGrant or award Stock Optionsderivative | +75,000 | $0.00 | $0 | 75,000 | Dec 20, 2024 |
| Dec 18, 2024 | Robert Gray director | AGrant or award Stock Optionsderivative | +19,752 | $0.00 | $0 | 19,752 | Dec 20, 2024 |
| Dec 18, 2024 | Matthew Jenusaitis director | AGrant or award Stock Optionsderivative | +19,752 | $0.00 | $0 | 19,752 | Dec 20, 2024 |
| Dec 18, 2024 | Sanjay Shrivastava director | AGrant or award Stock Optionsderivative | +19,752 | $0.00 | $0 | 19,752 | Dec 20, 2024 |
| Dec 19, 2024 | Robert Andrew Berman Chief Executive Officer | POpen-market purchase Common Stock | +12,000 | $2.55 | $31k | 222,236 | Dec 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Hamed AlaviChief Technology Officer
- Robert Andrew BermanChief Executive Officer
- Jennifer BrightChief Financial Officer
- Francis Duhaydirector
- Marc H. GlickmanSVP & Chief Medical Officer
- Robert Graydirector
- Matthew Jenusaitisdirector
- Sanjay Shrivastavadirector
Questions about NVNO
Answered from the filings on this page, as of the latest one.
Are insiders buying NVNO?
As of Sep 14, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $123 by 1 insider at enVVeno Medical Corp in the last 90 days, net -$123. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade NVNO on the open market?
Francis Duhay (director) sold $123 of NVNO on Sep 11, 2026 and filed the Form 4 on Sep 14, 2026. InsiderTell scored 0 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at enVVeno Medical Corp?
8 people have filed a Form 4 at enVVeno Medical Corp, among them Hamed Alavi (Chief Technology Officer), Robert Andrew Berman (Chief Executive Officer), Jennifer Bright (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.